Details for Patent: 6,852,708

Title:	Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls
Abstract:	For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of a form of Hyaluronic Acid selected from Hyaluronic Acid, salts thereof and combinations thereof to the animal to prevent narrowing of the tubular walls.
Inventor(s):	Falk; Rudolf Edgar (Toronto, CA), Ascuali; Samuel Simon (Toronto, CA), Turley; Eva Anne (Winnipeg, CA)
Assignee:	Jagotec AG (Hergisweik, CH)
Filing Date:	Dec 22, 1997
Application Number:	08/996,470
Claims:	1. A pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof wherein the concentration of the form of hyaluronic acid is 2% by weight of the composition, and (2) an agent selected from the group consisting of a non-steroidal anti-inflammatory drug, a restenosis inhibiting drug, Vitamin C, a free radical scavenger, an anti-oxidant and combinations thereof for inhibiting the narrowing of the vascular walls of an animal after the vascular walls have been traumatized, the amount of the form of hyaluronic acid being an effective non-toxic amount incorporated into the composition together with a therapeutically effective amount of the agent to inhibit vascular wall narrowing, wherein the amount of the form of hyaluronic acid is an effective amount to inhibit the narrowing of the vascular walls of the animal and the agent enhances the effect of the form of hyaluronic acid in the inhibition of the narrowing of the vascular walls, and wherein the form of hyaluronic acid is in an amount of between 10 mg to 1000 mg having a molecular weight of greater than 150,000 daltons and less than 750,000 daltons. 2. A method of inhibiting or reducing the adherence of smooth muscle cells, leukocytes, and/or platelets, the method comprising administering a therapeutically effective non-toxic amount of sodium hyaluronate to a human in need thereof, wherein the molecular weight of the sodium hyaluronate is greater than 150,000 daltons and less than 750,000 daltons. 3. The method of claim 2 wherein adherence of leukocytes or platelets is inhibited or reduced. 4. A method of inhibiting the adherence of smooth muscle cells, endothelial cells, leukocytes, platelets, cholesterol, or macrophages to vascular walls, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic arid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons. 5. A method of reducing the adherence of smooth muscle cells, endothelial cells, leukocytes, platelets, cholesterol, or macrophages to vascular walls, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic acid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic arid, pharmaceutically acceptable salts thereof and combinations thereof and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons. 6. The composition of claim 1 wherein the form of hyaluronic acid is sodium hyaluronate. 7. The composition of claim 1 wherein the composition is in injectable or intravenous form. 8. The composition of claim 1 wherein the amount of the form of hyaluronic acid is greater than 200 mg and the agent is a non-steroidal anti-inflammatory drug. 9. The method of claim 4 wherein adherence of leukocytes or platelets is inhibited. 10. The method of claim 4 wherein the form of hyaluronic acid is sodium hyaluronate. 11. The method of claim 4 wherein adherence of leukocytes or platelets is inhibited and wherein the form of hyaluronic acid is sodium hyaluronate. 12. The method of claim 5 wherein adherence of leukocytes or platelets is reduced. 13. The method of claim 5 wherein the form of hyaluronic acid is sodium hyaluronate. 14. The method of claim 5 wherein adherence of leukocytes or platelets is reduced and wherein the form of hyaluronic arid is sodium hyaluronate. 15. A method of inhibiting arterial restenosis comprising administering to a human a pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) a form of hyaluronic acid consisting of sodium hyaluronate, and (2) an agent selected from the group consisting of a non-steroidal anti-inflammatory drug, a restenosis inhibiting drug, Vitamin C, a free radical scavenger, an anti-oxidant and combinations thereof such that arterial restenosis after balloon angioplasty in humans is inhibited. 16. A method of inhibiting or reducing the adherence of leukocytes, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic acid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof, and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons. 17. A method of inhibiting or reducing the adherence of smooth muscle cells, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic acid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof, and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons. 18. A pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) sodium hyaluronate, and (2) an agent selected from the group consisting of a non-steroidal anti-inflammatory drug, a restenosis inhibiting drug, Vitamin C, a free radical scavenger, an anti-oxidant and combinations thereof for inhibiting the narrowing of the vascular walls of an animal after the vascular walls have been traumatized, the amount of the sodium hyaluronate being an effective non-toxic amount incorporated into the composition together with a therapeutically effective amount of the agent to inhibit vascular wall narrowing, wherein the amount of the sodium hyaluronate is an effective amount to inhibit the narrowing of the vascular walls of the animal and the agent enhances the effect of the sodium hyaluronate in the inhibition of the narrowing of the vascular walls, wherein sodium hyaluronate is in an amount of between 10 mg to 1000 mg and has a molecular weight of greater than 150,000 daltons and less than 750,000 daltons, and wherein the composition is in injectable or intravenous form. 19. A pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) sodium hyaluronate in an amount greater than 200 mg, and (2) a non-steroidal anti-inflammatory drug, which is present in a therapeutically effective amount to inhibit vascular wall narrowing, for inhibiting the narrowing of the vascular walls of an animal after the vascular walls have been traumatized, wherein the amount of the non-steroidal anti-inflammatory drug enhances the effect of the form of hyaluronic acid in the inhibition of the narrowing of the vascular walls, and wherein the sodium hyaluronate has a molecular weight of greater than 150,000 daltons and less than 750,000 daltons.